Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.66 |
| ▸ | ABL1 | P00519 | 5/20 | 0.66 |
| ▸ | BCR | P11274 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | ABL2 | P42684 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253796 | 0.88 | SRC (0.62) | SRCABL1BCREGFR | |
| SCHEMBL4894092 | 0.83 | SRC (0.65) | SRCABL1ABL2 | |
| SCHEMBL3990307 | 0.82 | SRC (0.72) | SRCABL1BCREGFRLCK | |
| SCHEMBL3219516 | 0.81 | SRC (0.75) | SRCABL1BCREGFR | |
| SCHEMBL3228976 | 0.81 | SRC (0.72) | SRCABL1BCREGFRLCK | |
| SCHEMBL22861713 | 0.81 | SRC (1.00) | SRCABL1BCRABL2 | |
| SCHEMBL15787878 | 0.80 | SRC (0.66) | SRCABL1BCREGFRLCK | |
| SCHEMBL4967200 | 0.79 | SRC (0.84) | SRCABL1BCR | |
| SCHEMBL13938749 | 0.78 | SRC (0.86) | SRCABL1BCR | |
| SCHEMBL3213030 | 0.78 | SRC (0.82) | SRCABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1268431-B1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | WYETH | 2004-09-09 | — | — | US | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | SRC 237/4885ABL1 126/4885BCR 647/4885 |
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | CYP19A1, SRC, CYP17A1 | SRC 2/4885ABL1 39/4885BCR 267/4885 |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | SRC 237/4885ABL1 126/4885BCR 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.